
    
      Participants with uveitic macular edema will be treated with one injection of intravitreal
      infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include
      best-corrected visual acuity, macular thickness as measured by optical coherence tomography,
      and electroretinogram responses.
    
  